Massachusetts Financial Services Co. MA Acquires 7,069 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Massachusetts Financial Services Co. MA lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 4.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 163,054 shares of the company’s stock after purchasing an additional 7,069 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Neurocrine Biosciences were worth $18,787,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC purchased a new position in Neurocrine Biosciences during the second quarter valued at $28,000. Innealta Capital LLC bought a new position in shares of Neurocrine Biosciences during the second quarter valued at $30,000. New Covenant Trust Company N.A. purchased a new position in shares of Neurocrine Biosciences in the 1st quarter worth about $32,000. EdgeRock Capital LLC bought a new position in Neurocrine Biosciences in the 2nd quarter worth about $35,000. Finally, Blue Trust Inc. grew its position in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after purchasing an additional 220 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX opened at $127.11 on Tuesday. The business’s fifty day moving average is $118.62 and its 200 day moving average is $131.89. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.52 and a fifty-two week high of $157.98. The company has a market capitalization of $12.87 billion, a PE ratio of 34.08 and a beta of 0.35.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a report on Friday, November 1st. Robert W. Baird boosted their price objective on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Citigroup increased their target price on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Piper Sandler upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $131.00 to $159.00 in a research note on Thursday, August 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Monday, September 16th. Five investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.